Ac­tivist in­vestor El­liott buys $1B+ stake in Bio­Marin as CEO change nears

The ac­tivist in­vest­ing gi­ant El­liott In­vest­ment Man­age­ment has bought over a $1 bil­lion stake in Bio­Marin, a per­son fa­mil­iar with the mat­ter tells End­points News.

El­liott’s in­volve­ment, first re­port­ed Tues­day by Reuters, is the lat­est de­vel­op­ment for the Cal­i­for­nia drug­mak­er, which has failed to meet its own sales tar­gets for the launch of its he­mo­phil­ia gene ther­a­py Roc­ta­vian. El­liott and Bio­Marin have been en­gaged in dis­cus­sions for sev­er­al months, ac­cord­ing to a per­son fa­mil­iar with the mat­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER